WALTHAM, Mass., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® today announced that positive results from the Phase 3 VALIANT study were presented as an oral ...

Pegcetacoplan significantly reduces proteinuria in patients with recurrent C3 glomerulopathy, or primary immune-complex ...

“I’m excited to now have a highly effective therapy for a broad range of patients living with C3G and primary IC-MPGN,” said Carla Nester, M.D., MSA, FASN, lead principal investigator for the VALIANT ...

STOCKHOLM, Dec. 12, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive ...

Credit: Apellis. Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

Apellis and Sobi's Aspaveli application for C3G and IC-MPGN treatment validated by the EMA, addressing rare kidney diseases. Apellis Pharmaceuticals and Sobi announced that the European Medicines ...

The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) supplemental New Drug Application (sNDA) for ...

WALTHAM, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that TheNew England Journal of Medicine (NEJM) published positive results from the Phase ...

"Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market"Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) is a rare and progressive form of glomerular disease marked ...

Significant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR ≤0.5 g/g)achieved in one-third of ...

Proven efficacy across all three key markers of disease-68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Broad label includes adults and ...

Proven efficacy across all three key markers of disease-68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Conference call tomorrow at 8:00 a.m.